Defender Capital Opposes STAAR Surgical's Sale to Alcon, Advocating for Independent Growth

Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon

Defender Capital, a long-term shareholder of STAAR Surgical Company, publicly voices its opposition to the proposed sale of the company to Alcon Inc. The firm, which holds approximately 1.5% of STAAR's outstanding common stock, argues that the deal undervalues the company and comes at an inopportune time. With STAAR recently reporting stabilization in its performance and showcasing growth potential in a market increasingly affected by vision-related issues, Defender believes that the sale does not align with the interests of shareholders. The timing of the announcement, just ahead of STAAR's second quarter earnings report, raises further concerns about the strategic decision-making of the Board of Directors.

Defender Capital highlights that STAAR has a promising future, particularly as global demographics shift towards an aging population that requires enhanced vision care. The increasing reliance on digital screens further exacerbates vision challenges, creating a growing market for STAAR's innovative products. Defender asserts that the Board’s current focus on the sale to Alcon distracts from the company’s potential to thrive independently. They emphasize the importance of allowing shareholders to have a say in the company's strategic direction, which they feel has been overlooked due to the Board's actions.

The dissent regarding the proposed sale is echoed by other stakeholders, including Broadwood Partners, a major shareholder of STAAR, which supports the company's independent future and has engaged constructively with the Board following the recent vote. The opposition is further bolstered by critiques from governance advisory firms; Glass Lewis has recommended voting against the sale, while ISS has labeled the sales process as fundamentally flawed. Defender Capital expresses concern that some hedge funds were attracted to STAAR's shares due to the allure of Alcon's all-cash offer, unaware of the significant shareholder resistance. The subsequent decline in STAAR's stock price after this realization highlights the contentious nature of the proposed deal and raises questions about the Board’s commitment to maximizing long-term shareholder value.

In conclusion, the ongoing debate surrounding STAAR Surgical's potential sale to Alcon underscores the complexities of corporate governance and shareholder interests. As stakeholders like Defender Capital and Broadwood Partners advocate for an independent STAAR, the outcome of this situation will likely have lasting implications for the company’s strategic direction and market position. The pushback from both investors and advisory firms signals a critical moment for STAAR as it navigates its future in a rapidly evolving industry.